查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004656

乳癌液態生物檢體設備市場：按技術、檢測類型、檢體類型、適應症、應用和最終用戶分類——2026-2032年全球市場預測

Breast Cancer Liquid Biopsy Testing Devices Market by Technology, Test Type, Sample Type, Indication, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，乳癌液態生物檢體設備市場價值將達到 12.3 億美元，到 2026 年將成長至 14.5 億美元，到 2032 年將達到 44.6 億美元，複合年成長率為 20.13%。

主要市場統計數據
基準年 2025 12.3億美元
預計年份：2026年 14.5億美元
預測年份 2032 44.6億美元
複合年成長率 (%) 20.13%

重點關注液態生物檢體在乳癌治療和創新路徑中不斷變化的作用。

液態生物檢體技術已從小眾研究工具發展成為精準腫瘤學的關鍵組成部分，為檢測腫瘤來源的生物標記提供了微創的組織切片檢查替代方案。隨著臨床團隊尋求更快、更安全、更可重複的腫瘤動態監測方法，液態生物檢體檢測設備為改善早期檢測、指南治療方法選擇和追蹤微小殘留病灶提供了機會。本文首先闡明循環腫瘤DNA、循環性腫瘤細胞和細胞外囊泡（如外泌體）的科學基礎，並解釋檢測的敏感度、特異性和通量如何影響其臨床應用，從而奠定了微量殘存疾病技術的基礎。

變革性的變化正在重塑乳癌液態生物檢體。

液態生物檢體診斷設備領域正經歷快速變革，這主要得益於檢測化學、儀器靈敏度和生物資訊技術的進步。用於檢測低頻突變的高解析度技術以及結合ctDNA、CTC和外泌體成分的多參數分析方法，正在拓展其臨床應用。同時，檢體處理和標準化的進步降低了分析前的變異性，從而實現了更可靠的時間序列監測。這些技術進步，加上臨床指引的不斷發展（這些指引日益重視微創診斷在治療方法選擇和疾病後續觀察評估中的價值），進一步提升了液體切片的價值。

評估 2025 年美國關稅變化對診斷設備製造商的供應鏈、成本和策略採購的累積影響。

美國近期關稅調整對整個醫療設備供應鏈產生了影響，促使診斷設備製造商重新評估籌資策略和成本結構。微流體晶片、特殊聚合物和半導體光學元件等對數位PCR和定序設備至關重要的組件可能面臨更高的運輸成本，迫使供應商考慮近岸外包、雙重採購或重新設計組件等替代方案。對於垂直整合試劑和耗材的供應商而言，關稅帶來的價格壓力可能會影響利潤率，並加速與契約製造就長期供應合約進行談判。

深入了解關鍵細分市場，揭示技術選擇、應用、使用者環境、測試方法、檢體工作流程、臨床適應症和通路。

細分分析揭示了創新和應用集中在哪些領域，以及某些平台在特定應用場景中廣受歡迎的原因。技術細分比較了數位PCR、次世代定序和即時PCR。數位PCR進一步分為晶片式和液滴式數位PCR；次世代定序分為標靶定序、全EXOME定序和全基因測序；即時PCR分為染料法和探針法。這些差異會影響分析靈敏度、多重檢測能力和單次檢測成本，進而影響臨床應用率。

關鍵區域見解解釋了主要區域的部署趨勢、醫療保健系統優先事項和法規結構有何不同，以及它們如何影響部署策略。

區域趨勢影響液態生物檢體檢測設備在腫瘤治療路徑中的應用、報銷和整合。在美洲，由於分散式檢查基礎設施和蓬勃發展的私人實驗室產業，臨床網路和學術機構通常主導初步的臨床檢驗和應用。相較之下，歐洲、中東和非洲（EMEA）地區的格局更為複雜，監管協調和公共報銷框架的完善影響著液體活體組織切片設備的普及，而集中式標準實驗室則與醫療保險機構合作，以證明其健康經濟價值。在亞太地區，基因組基礎設施的快速投資、不斷擴大的臨床試驗活動以及多樣化的公私合營醫療模式，為集中式和照護現場（POC​​）解決方案創造了機會。

主要企業洞察整合了競爭性提案、差異化策略和合作模式，從而塑造了診斷開發公司的競爭格局。

領先的診斷公司和新興的專業公司正在採取互補策略來實現產品差異化。一些公司專注於平台層面的整合，將高靈敏度儀器、專有試劑和雲端分析功能結合，建構強大的生態系統，從而鎖定實驗室客戶。另一些公司則專注於特定的臨床適應症和檢體類型，最佳化檢測方法的化學特性，以用於早期檢測和微量殘存疾病監測，在這些領域，超高的靈敏度和特異性至關重要。受託研究機構(CRO) 和臨床實驗室也發揮關鍵作用，在監管部門核准之前，為新型檢測方法提供檢驗流程和規模化生產能力。

為旨在擴大臨床應用、最佳化產品市場契合度並維持液態生物檢體檢測競爭優勢的行業領導者提供實用建議。

為了將科學進步轉化為商業性成功，產業領導者應優先考慮創建與特定臨床應用案例相符的策略證據。這包括設計能夠證明產品在早期檢測、復發檢測或治療監測方面具有臨床附加價值的研究，並在臨床路徑開發的早期階段就與關鍵意見領袖進行溝通。同時，應投資穩健的樣本製備流程以及與實驗室資訊系統的互通性，以最大限度地減少醫院檢查室和參考中心採用該產品的障礙。此外，製造商應探索混合商業化模式，將面向客戶的高觸感達直銷與透過線上通路和經銷商開展的合作相結合，以擴大其市場覆蓋範圍。

本報告描述了調查方法，包括跨學科方法、資料三角測量和檢驗程序，這些都構成了所提出的研究結果和見解的基礎。

本調查方法整合了技術文獻綜述、監管和政策分析以及結構化的相關人員對話，以確保觀點平衡且實用。主要資訊來源包括對臨床專業人員、實驗室經理、採購經理和行業高管的訪談，以了解實際操作、推廣應用障礙和商業化策略。二級資訊來源包括同行評審文章、會議論文集以及公開的監管文件和指導文件，這些資料構成了檢測性能和臨床效用技術說明的基礎。

總結了下一階段臨床和商業開發的機會領域、當前挑戰和策略重點。

液態生物檢體設備在技術、臨床需求和醫療保健系統優先事項的交匯點佔據著至關重要的地位。非侵入性檢測腫瘤訊號的能力不斷增強，為改善早期檢測、最佳化預後和加強治療監測提供了實際的機會。然而，要實現這些機會，需要解決技術差異性問題，使證據產生與支付方的期望相符，並確保工作流程與臨床檢查室操作無縫銜接。目前面臨的挑戰包括：標準化樣本製備流程、證明療效的顯著改善，以及建立能夠反映診斷價值的永續報銷機制。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章乳癌液態生物檢體設備市場：依技術分類

  • 數位PCR
    • 基於晶片的數位PCR
    • 液滴式數位PCR
  • 次世代定序
    • 目標序列
    • 全EXOME定序
    • 全基因組定序
  • 即時PCR
    • 基於染料的PCR
    • 基於探針的PCR

第9章：乳癌液態生物檢體設備市場（依檢測類型分類）

  • 用於體外診斷
    • 裝置
    • 試劑
  • 實驗室開發的測試
    • 基於NGS的LDT
    • 基於PCR的LDT

第10章檢體類型分類的乳癌液態生物檢體設備市場

  • 電漿
  • 血清
  • 全血

第11章乳癌液態生物檢體設備市場：依適應症分類

  • 早期檢測
  • 預後
  • 復發檢測
  • 治療監測

第12章乳癌液態生物檢體設備市場：依應用領域分類

  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 外泌體
    • 外泌體DNA
    • 外泌體RNA

第13章乳癌液態生物檢體設備市場：依最終用戶分類

  • 合約研究機構
  • 診斷檢測實驗室
  • 醫院和診所
  • 研究機構

第14章乳癌液態生物檢體設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章乳癌液態生物檢體設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章乳癌液態生物檢體設備市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國乳癌液態生物檢體設備市場

第18章：中國乳癌液態生物檢體設備市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Angle plc
  • Biocept Inc.
  • Cynvenio Biosystems Inc.
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Fluxion Biosciences Inc.
  • GRAIL LLC
  • Guardant Health Inc.
  • Illumina Inc.
  • Inivata Ltd.
  • Lucence Health Pte Ltd
  • Menarini Silicon Biosystems
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories
  • Personal Genome Diagnostics Inc.
  • Predicine Inc.
  • Qiagen NV
  • Resolution Bioscience Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trovagene Inc.
  • Vortex Biosciences
Product Code: MRR-742BD517C0D8

The Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 1.23 billion in 2025 and is projected to grow to USD 1.45 billion in 2026, with a CAGR of 20.13%, reaching USD 4.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.23 billion
Estimated Year [2026] USD 1.45 billion
Forecast Year [2032] USD 4.46 billion
CAGR (%) 20.13%

A focused introduction to the evolving role of liquid biopsy testing in breast cancer care and innovation pathways

Liquid biopsy technologies have moved from niche research tools to pivotal components of precision oncology, offering minimally invasive alternatives to tissue biopsies for detecting tumor-derived biomarkers. As clinical teams seek faster, safer, and more repeatable modalities to monitor tumor dynamics, liquid biopsy testing devices present opportunities to improve early detection, guide therapeutic selection, and track minimal residual disease. This introduction sets the stage by clarifying the scientific underpinnings-circulating tumor DNA, circulating tumor cells, and extracellular vesicles such as exosomes-and by describing how assay sensitivity, specificity, and throughput shape clinical applicability.

Transitioning from bench to bedside requires alignment across assay platforms, sample handling protocols, and data interpretation frameworks. Regulatory pathways and reimbursement considerations further influence adoption timelines, while vendor investments in assay validation, automation, and interoperability determine competitive positioning. Ultimately, stakeholders must balance technical performance with workflow compatibility, cost-efficiency, and clinical utility to realize the promise of liquid biopsy testing devices in routine breast cancer management.

Transformative shifts reshaping technology, clinical practice, and commercialization in breast cancer liquid biopsy testing

The landscape of liquid biopsy testing devices has undergone rapid transformation driven by advances in assay chemistry, instrument sensitivity, and bioinformatics. High-resolution techniques that detect low-frequency variants and multi-analyte approaches combining ctDNA, CTCs, and exosomal content are expanding clinical use cases. Concurrently, improvements in sample processing and standardization have reduced pre-analytical variability, enabling more reliable longitudinal monitoring. These technical gains are complemented by evolving clinical guidelines that increasingly recognize the value of minimally invasive diagnostics for treatment selection and disease surveillance.

On the commercialization front, strategic collaborations between diagnostic developers, clinical laboratories, and oncology centers are accelerating evidence generation and real-world validation. Partners are prioritizing scalable workflows and cloud-enabled analytics to support decentralized testing and remote monitoring. Moreover, payer dialogue has shifted toward value-based reimbursement for diagnostics that demonstrably improve outcomes or reduce downstream costs. Taken together, these shifts create a convergence of scientific maturity and commercial readiness that is changing how clinicians and health systems approach breast cancer detection and management.

Assessing the cumulative impact of United States tariff changes in 2025 on supply chains, costs, and strategic sourcing for diagnostic device manufacturers

Recent tariff adjustments in the United States have reverberated across medical device supply chains, prompting diagnostic manufacturers to reassess sourcing strategies and cost structures. Components such as microfluidic chips, specialty polymers, and semiconductor-based optics that are integral to digital PCR and sequencing instruments may face higher landed costs, compelling vendors to evaluate nearshoring, dual sourcing, or redesign for component substitution. For vertically integrated suppliers of reagents and consumables, tariff-induced price pressure can affect margin profiles and may accelerate negotiations with contract manufacturers to secure long-term supply agreements.

In response to these pressures, some organizations are intensifying supplier qualification and inventory management practices while accelerating investments in local manufacturing capabilities to mitigate exposure. Regulatory and logistics teams are also collaborating more closely to ensure continuity of reagent supply and to minimize disruptions to clinical testing services. As a result, procurement decisions increasingly weigh not only unit cost but also supply resilience, lead times, and inventory carrying implications, shaping longer-term strategic planning across the diagnostic ecosystem.

Key segmentation insights that illuminate technological choices, applications, user environments, testing approaches, specimen workflows, clinical indications, and distribution pathways

Segmentation analysis clarifies where innovation and adoption are concentrated and why certain platforms gain traction in specific use cases. Technology segmentation compares digital PCR, next generation sequencing, and real time PCR, with digital PCR further differentiated into chip based and droplet digital formats, next generation sequencing spanning targeted sequencing, whole exome sequencing, and whole genome sequencing, and real time PCR evaluated across dye based and probe based chemistries. These distinctions matter for analytical sensitivity, multiplexing capacity, and cost per assay, which in turn influence clinical uptake.

Application segmentation assesses circulating tumor cells, circulating tumor DNA, and exosomes, with exosomes further disaggregated into exosomal DNA and exosomal RNA; each analyte class offers distinct biological insight and requires tailored extraction and analysis workflows. End user segmentation highlights contract research organizations, diagnostic laboratories, hospitals and clinics, and research centers as primary adopters, with differing demands for throughput, turnaround time, and regulatory compliance. Test type segmentation contrasts in vitro diagnostic instruments and reagents against laboratory developed tests, noting that in vitro diagnostics split into instrument and reagent categories while laboratory developed tests are often grouped as NGS based LDTs and PCR based LDTs, each with unique validation and commercialization pathways.

Sample type segmentation examines plasma, serum, and whole blood as critical pre-analytical variables that affect yield and assay performance. Indication segmentation differentiates early detection, prognosis, recurrence detection, and treatment monitoring as distinct clinical endpoints that drive assay selection and evidence generation. Finally, distribution channel segmentation contrasts direct sales, online sales, and third party distributors, recognizing that online sales may occur via e-commerce platforms or manufacturer websites, which impacts channel strategy, pricing, and customer support. Integrating these segmentation perspectives reveals where vendors should concentrate R&D, regulatory efforts, and commercial resources to align product features with end-user needs and clinical value.

Key regional insights that explain how adoption dynamics, health system priorities, and regulatory frameworks vary across major global regions and influence deployment strategies

Regional dynamics shape how liquid biopsy testing devices are adopted, reimbursed, and integrated with oncology pathways. In the Americas, clinical networks and academic centers often drive early clinical validation and adoption, supported by infrastructure for decentralized testing and an active private laboratory sector. Meanwhile, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts and public reimbursement frameworks influence uptake, and where centralized reference laboratories collaborate with healthcare payers to demonstrate health economic value. In Asia-Pacific, rapid investments in genomics infrastructure, expanding clinical trial activity, and diverse public-private healthcare models create opportunities for both centralized and point-of-care solutions.

These regional differences affect product design, from instrument footprint and reagent cold-chain requirements to language localization and integration with electronic health records. Market entry strategies must therefore be tailored: some regions prioritize extensive clinical utility data and health technology assessments, whereas others emphasize cost-efficiency and scalable deployment. Strategic partnerships with regional laboratory networks, key opinion leaders, and local regulatory experts are essential to accelerate clinical adoption and to navigate payer negotiations across these varied geographies.

Key company insights that synthesize competitive offers, differentiation strategies, and collaboration patterns shaping the competitive landscape for diagnostic developers

Leading diagnostic companies and emerging specialists are pursuing complementary approaches to differentiate their offerings. Some firms emphasize platform-level integration-pairing high-sensitivity instruments with proprietary reagents and cloud-based analytics-to create defensible ecosystems that lock in laboratory customers. Other organizations focus on niche clinical indications or specimen types, optimizing assay chemistry for early detection or minimal residual disease monitoring where ultra-high sensitivity and specificity are prerequisites. Contract research organizations and clinical service laboratories also play a critical role, providing validation pipelines and scaling capabilities for novel assays prior to regulatory clearance.

Partnerships between technology providers, academic centers, and oncology networks have become a primary vehicle for generating clinical evidence and accelerating guideline inclusion. Strategic M&A activity and licensing agreements continue to reconfigure capability stacks, enabling some vendors to bridge gaps in bioinformatics, sample processing, or global distribution. For decision-makers, choosing partners and suppliers involves balancing technical merit, evidence generation capacity, and commercialization reach to achieve durable clinical and commercial outcomes.

Actionable recommendations for industry leaders aiming to scale clinical adoption, optimize product-market fit, and sustain competitive advantage in liquid biopsy testing

To translate scientific advances into commercial success, industry leaders should prioritize strategic evidence generation that aligns with specific clinical use cases. Design studies that demonstrate incremental clinical value in early detection, recurrence detection, or therapy monitoring, and engage key opinion leaders early to shape clinical pathways. In parallel, invest in robust pre-analytical workflows and interoperability with laboratory information systems to minimize barriers to adoption among hospital laboratories and reference centers. Manufacturers should also evaluate hybrid commercialization approaches that combine direct sales for high-touch accounts with online channels and distributor relationships to broaden reach.

Operationally, strengthening supply chain resilience through diversified sourcing, local manufacturing options, or longer-term supplier agreements will reduce exposure to tariff and logistics risks. From a product perspective, prioritize modularity and software-enabled upgrades so instruments can evolve with bioinformatic advances without requiring full hardware replacement. Finally, pursue payer engagement strategies that frame diagnostics as value drivers, collaborating on outcomes studies and real-world evidence generation to support reimbursement conversations and long-term adoption.

Research methodology that explains the multidisciplinary approach, data triangulation, and validation steps underpinning the report's findings and insights

The research methodology integrates technical literature review, regulatory and policy analysis, and structured stakeholder engagement to ensure a balanced and actionable perspective. Primary inputs include interviews with clinical experts, laboratory directors, procurement leads, and industry executives to capture operational realities, adoption barriers, and commercialization strategies. Secondary sources span peer-reviewed publications, conference proceedings, and publicly available regulatory filings and guidance documents to ground technical statements about assay performance and clinical utility.

Analysts conducted a rigorous triangulation process to cross-validate findings, reconciling interview insights with published evidence and product specifications. Where possible, methodological transparency was maintained by documenting inclusion criteria for studies, the scope of stakeholder interviews, and the rationale for interpreting clinical endpoints. This approach ensures that conclusions reflect both the latest scientific understanding and real-world constraints that influence implementation and scale-up of liquid biopsy testing devices.

Concluding synthesis that encapsulates opportunity areas, persistent challenges, and strategic priorities for the next phase of clinical and commercial development

Liquid biopsy testing devices occupy a pivotal intersection of technology, clinical need, and health system priorities. The growing capability to detect tumor-derived signals noninvasively presents tangible opportunities to improve early detection, refine prognosis, and enhance treatment monitoring. Nonetheless, realization of these opportunities hinges on addressing technical variability, aligning evidence generation with payer expectations, and ensuring that workflows integrate seamlessly with clinical laboratory operations. Persistent challenges include harmonizing pre-analytical practices, demonstrating clear outcome improvements, and creating sustainable reimbursement pathways that reflect the diagnostic's value contribution.

Looking ahead, stakeholders who combine rigorous clinical validation, pragmatic product design, and strategic partnerships will be best positioned to translate assays into widely adopted clinical tools. Emphasizing modular platforms, resilient supply chains, and engagement with regulatory and payer ecosystems will accelerate adoption. In sum, the next phase requires coordinated action across developers, clinicians, laboratories, and health systems to transform promising technologies into routine components of breast cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Liquid Biopsy Testing Devices Market, by Technology

  • 8.1. Digital PCR
    • 8.1.1. Chip Based Digital PCR
    • 8.1.2. Droplet Digital PCR
  • 8.2. Next Generation Sequencing
    • 8.2.1. Targeted Sequencing
    • 8.2.2. Whole Exome Sequencing
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Real Time PCR
    • 8.3.1. Dye Based PCR
    • 8.3.2. Probe Based PCR

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Test Type

  • 9.1. In Vitro Diagnostic
    • 9.1.1. Instruments
    • 9.1.2. Reagents
  • 9.2. Laboratory Developed Test
    • 9.2.1. NGS Based LDT
    • 9.2.2. PCR Based LDT

10. Breast Cancer Liquid Biopsy Testing Devices Market, by Sample Type

  • 10.1. Plasma
  • 10.2. Serum
  • 10.3. Whole Blood

11. Breast Cancer Liquid Biopsy Testing Devices Market, by Indication

  • 11.1. Early Detection
  • 11.2. Prognosis
  • 11.3. Recurrence Detection
  • 11.4. Treatment Monitoring

12. Breast Cancer Liquid Biopsy Testing Devices Market, by Application

  • 12.1. Circulating Tumor Cells
  • 12.2. Circulating Tumor DNA
  • 12.3. Exosomes
    • 12.3.1. Exosomal DNA
    • 12.3.2. Exosomal RNA

13. Breast Cancer Liquid Biopsy Testing Devices Market, by End User

  • 13.1. Contract Research Organizations
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals And Clinics
  • 13.4. Research Centers

14. Breast Cancer Liquid Biopsy Testing Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Breast Cancer Liquid Biopsy Testing Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Breast Cancer Liquid Biopsy Testing Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Breast Cancer Liquid Biopsy Testing Devices Market

18. China Breast Cancer Liquid Biopsy Testing Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Angle plc
  • 19.7. Biocept Inc.
  • 19.8. Cynvenio Biosystems Inc.
  • 19.9. Epic Sciences Inc.
  • 19.10. Exact Sciences Corporation
  • 19.11. F. Hoffmann-La Roche Ltd
  • 19.12. Fluxion Biosciences Inc.
  • 19.13. GRAIL LLC
  • 19.14. Guardant Health Inc.
  • 19.15. Illumina Inc.
  • 19.16. Inivata Ltd.
  • 19.17. Lucence Health Pte Ltd
  • 19.18. Menarini Silicon Biosystems
  • 19.19. Myriad Genetics Inc.
  • 19.20. NeoGenomics Laboratories
  • 19.21. Personal Genome Diagnostics Inc.
  • 19.22. Predicine Inc.
  • 19.23. Qiagen N.V.
  • 19.24. Resolution Bioscience Inc.
  • 19.25. Sysmex Corporation
  • 19.26. Thermo Fisher Scientific Inc.
  • 19.27. Trovagene Inc.
  • 19.28. Vortex Biosciences

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES